This is an automatically translated article.
Omeprazole is an active ingredient in the proton pump inhibitor group, which works by inhibiting the proton pump H + K + ATPase of the parietal cells of the stomach. This is also the main active ingredient in Omepraglobe. What does omepraglobe do?
1. What is Omepraglobe?
The active ingredient Omepraglobe is Omeprazole 20mg. The drug is manufactured by Globela Pharma PVT., Ltd. - INDIA, circulating in Vietnam with registration number VN-5270-10.2. What does Omepraglobe do?
Omepraglobe is indicated for use in the following medical conditions:
Gastroesophageal reflux disease (GERD); Treatment of gastrointestinal ulcers; Zollinger-Ellison syndrome.
3. Dosage - How to take Omepraglobe
Omepraglobe should be swallowed whole and should not be crushed or chewed before taking.
Omepraglobe used to relieve symptoms of acid indigestion: Dose 10 or 20 mg / day, used for 2 - 4 weeks. Treatment of gastroesophageal reflux syndrome (GERD): The usual dose of Omepraglobe: 20 mg x 1 time / day, used for 4 weeks, an additional 4 - 8 weeks if the patient has not completely recovered. In the case of patients with persistent esophagitis, the dose of Omepraglobe 40mg/day can be used. The maintenance dose of Omepraglobe after healing of esophagitis is 20mg once daily and in acid reflux is 10mg/day. Treatment of peptic ulcers: Single dose Omepraglobe 20mg/day, or can be increased to 40mg/day in severe cases. Continue Omepraglobe treatment for 4 weeks for duodenal ulcers and 8 weeks for gastric ulcers. Omepraglobe maintenance dose: 10-20 mg x 1 time / day. Treatment of Helicobacter pylori in peptic ulcers: Omepraglobe can be combined with other antibiotics in dual or triple therapy. Dual therapy: Omepraglobe 20mg x 2 times/day used continuously for 2 weeks. Triple therapy: Omepraglobe 20mg twice a day for 1 week. Treatment of gastric ulcer caused by the use of non-steroidal anti-inflammatory drugs: Omepraglobe dose 20mg/day. Doses of 20 mg/day have also been used to prevent ulcers in patients with a history of gastrointestinal injury who must continue to be treated with nonsteroidal anti-inflammatory drugs. Zollinger - Ellison syndrome: use Omepraglobe at a dose of 60mg x 1 time / day or adjust the dose when necessary. Most patients have effective symptom control at doses ranging from 20 to 120 mg/day, but doses of Omepraglobe up to 120 mg 3 times/day can be used. Omepraglobe dosage above 80 mg per day should be divided into 2 oral doses. Prevention of acid aspiration during general anesthesia: use a dose of Omepraglobe 40 mg the evening before surgery and use an additional 40 mg, 2 - 6 hours before the procedure. Patients with impaired renal function: No dose adjustment of Omepraglobe is required in patients with impaired renal function. Patients with liver failure: use Omepraglobe at a dose of 10 - 20 mg/day. Elderly (>65 years): No dose adjustment of Omepraglobe is required in the elderly. Children: Experience in the treatment of Omepraglobe in children is very limited.
4. Contraindications of Omepraglobe
Omepraglobe is contraindicated in patients with hypersensitivity to Omeprazol, Esomeprazole or other Benzimidazole derivatives (Lansoprazol, Pantoprazol, Rabeprazol) or to any of the ingredients in Omepraglobe.
5. Omepraglobe side effects
Common side effects of Omepraglobe:
Headache, drowsiness, dizziness; Nausea, vomiting, abdominal pain, diarrhea or constipation, bloating. Uncommon side effects of Omepraglobe:
Insomnia, confusion, dizziness, fatigue; Urticaria, itching, rash; Reversible increase in transaminases. Rare side effects of Omepraglobe:
Sweating, peripheral edema, hypersensitivity causing angioedema, fever and anaphylaxis; Leukopenia, thrombocytopenia and total blood cell reduction; Confusion, agitation, depression, hallucinations in elderly patients, especially in critically ill patients, hearing disorders; Large breasts in men. Gastritis; Candida infection ; Dry mouth. Jaundice hepatitis or not, encephalopathy in people with liver failure; Bronchospasm; Joint - muscle pain. Interstitial nephritis.
6. Be careful when using Omepraglobe
If a patient using Omepraglobe has symptoms such as: a lot of weight loss, prolonged vomiting, difficulty swallowing, vomiting blood or vomiting black stools, suspected or ongoing stomach ulcer: the patient should exclude the possibility malignancy because treatment with Omepraglobe can alleviate symptoms and delay diagnosis. The combination of proton pump inhibitors (PPIs) such as Omepraglobe and Atazanavir is not recommended. If necessary, closely monitor clinical manifestations (such as viral infection) in combination with increasing the dose of Atazanavir to 400mg and 100mg of Ritonavir, without increasing the dose of Omepraglobe. As with other acid blockers, Omepraglobe may decrease the absorption of vitamin B12 (cyanocobalamin), so this should be considered in patients with reduced body stores or at risk. Decreased absorption of vitamin B12 if taking Omepraglobe for a long time. Omeprazole is an inhibitor of CYP2C19, when starting or ending treatment with Omepraglobe, the risk of drug interactions with drugs metabolised by CYP2C19 should be taken into account. When monitoring Clopidogrel and Omeprazole, the correlation of this interaction is not clear but as a precaution, clopidogrel and Omepraglobe should not be used concomitantly. Severe hypomagnesaemia has been reported in patients treated with PPIs such as Omepraglobe for at least 3 months. Most cases of Omepraglobe treatment about 1 year with symptoms of hypomagnesaemia such as fatigue, muscle spasms, delirium, convulsions, dizziness, ventricular arrhythmias... occur insidiously and usually do not be noticed. This condition may improve after magnesium supplementation and discontinuation of PPIs such as Omepraglobe. Long-term (>1 year) use of PPIs such as high-dose Omepraglobe may slightly increase the risk of hip, wrist, and spine fractures, mainly in the elderly or those with risk factors other.Patients at risk of osteoporosis should be supplemented with vitamin D and calcium. Pregnant women: Experimental studies have not found that omeprazole has the potential to cause malformations and toxicity to the fetus, however, Omepraglobe should not be used in pregnant women, especially during the first 3 months of pregnancy. Lactation: Omepraglobe is not recommended for use in nursing mothers. Omepraglobe is unlikely to affect the ability to drive or use machines because of the risk of side effects such as dizziness and visual disturbances.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
